Latest News for: amyotrophic lateral sclerosis

Edit

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

PR Newswire 25 Aug 2025
This proprietary immunomodulatory biologic combination therapy is being developed for the treatment of patients with amyotrophic lateral sclerosis (ALS).  ... About Amyotrophic Lateral Sclerosis.
Edit

Amyotrophic Lateral Sclerosis Clinical Trials, Companies, Therapies, Pipeline | Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, ...

GetNews 22 Aug 2025
DelveInsight’s, “Amyotrophic Lateral Sclerosis (ALS) – Pipeline Insight, 2025,” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis (ALS) pipeline landscape.
Edit

Amyotrophic Lateral Sclerosis Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

GetNews 13 Aug 2025
The Amyotrophic Lateral Sclerosis epidemiology section provides insights into the historical and current Amyotrophic Lateral Sclerosis patient pool and forecasted trends for seven individual major countries.
Edit

Amyotrophic Lateral Sclerosis Pipeline Insight 2025: 75+ Companies Accelerating Innovation Across Genetic and Neuroinflammatory Targets ...

GetNews 26 Jul 2025
• DelveInsight’s amyotrophic lateral sclerosis pipeline analysis depicts a strong space with 75+ active players working to develop 80+ pipeline drugs for amyotrophic lateral sclerosis treatment.
Edit

Amyotrophic Lateral Sclerosis (ALS) Market Forecast Report 2025-2034 | Advancements in Therapeutics and Approved Medications ...

Nasdaq Globe Newswire 23 Jul 2025
Rising ALS prevalence, demand for treatments, and advancing research propel growth ... Rising ALS prevalence, demand for treatments, and advancing research propel growth ... .
Edit

Amyotrophic Lateral Sclerosis (ALS) Market Analysis Report 2025-2035: Breakthrough Therapeutic Solutions Emerge in ALS Treatment ...

The Galveston Daily News 21 Jul 2025
DUBLIN--(BUSINESS WIRE)--Jul 21, 2025-- ....
Edit

Amyotrophic Lateral Sclerosis (ALS) Market Analysis Report 2025-2035 | Increase in Clinical Trials and Investments ...

Nasdaq Globe Newswire 14 Jul 2025
The ALS market is witnessing robust growth driven by increased disease awareness, advancements in genetic research, and an expanding pipeline of therapeutic drugs ... Key challenges include high treatment costs and limited awareness in emerging markets ... .
Edit

Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis (“ALS” or “Lou Gehrig’s Disease”) (Form 8-K) (Klotho Neuroscience Inc)

Public Technologies 10 Jul 2025
) ... Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease") ... (Nasdaq ... Less than two years later, at the age of 37, Gehrig died of complications from ALS ... (noodl.
Edit

Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")

PR Newswire 10 Jul 2025
NEW YORK, July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq ... Joseph Sinkule, Klotho's Chief Executive Officer ... Sinkule ... Less than two years later, at the age of 37, Gehrig died of complications from ALS ... (NASDAQ ... 440k+. Newsrooms & ... .
Edit

Amyotrophic Lateral Sclerosis Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the ...

GetNews 08 Jul 2025
Inactive Products Amyotrophic Lateral Sclerosis Key Companies Amyotrophic Lateral Sclerosis Key Products Amyotrophic Lateral Sclerosis- Unmet Needs Amyotrophic Lateral Sclerosis- Market Drivers and ...
Edit

Amyotrophic Lateral Sclerosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | ...

GetNews 26 Jun 2025
DelveInsight’s, “Amyotrophic Lateral Sclerosis (ALS) – Pipeline Insight, 2025,” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis (ALS) pipeline landscape.
Edit

Pharmather Secures Key US Patent For Ketamine In Amyotrophic Lateral Sclerosis (ALS), Bolstering Its Orphan ...

MENA FN 24 Jun 2025
(MENAFN - GlobeNewsWire - Nasdaq) TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB. PHRRF) (CSE. PHRM) ("PharmaTher" or the "Company"), a company focused on unlocking the ... .
Edit

Amyotrophic Lateral Sclerosis Treatment Market To Observe Growth at a CAGR of 6.1% by 2033 ...

Nasdaq Globe Newswire 23 Jun 2025
The global amyotrophic lateral sclerosis treatment market is undergoing gradual yet impactful transformation, driven by advancements in neurodegenerative disease research, gene-targeted therapies, and biomarkers innovation.
Edit

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis ...

Business Wire 05 Jun 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ ... The presentation can be found here.
Edit

Faulty cellular 'energy supply' in Amyotrophic Lateral Sclerosis (King's College London)

Public Technologies 19 May 2025
). A new study, published today in Nature Communications, found that two common gene mutations in ALS are linked to mitochondrial dysfunction ... Mutations in genes FUS and TARDBP are known to cause ALS, the most common motor neuron disease (MND) ... C9orf72.

Article Search

tools
×
×
×
×